Navigation Links
BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Stock Repurchase Program
Date:12/12/2013

harmaceuticals Ltd. has the marketing rights for XIAFLEX for the treatment of Dupuytren's contracture in Canada and Australia, and Swedish Orphan Biovitrum AB markets CCH as XIAPEX® (the EU tradename for CCH) for the treatment of Dupuytren's contracture in 71 Eurasian and African countries. In December 2013, the U.S. Food & Drug Administration (FDA) approved XIAFLEX for the treatment of Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome and expects to initiate next stage trials in the fourth quarter of 2013. Auxilium is also testing CCH as a treatment for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase 2 trials, and expects to report top-line data from these trials in the fourth quarter of 2013. For more information, please visit www.biospecifics.com.

Forward Looking Statements
This release includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements." The forward-looking statements include statements concerning, among other things, the repurchasing by BioSpecifics of its common stock and the confidence that BioSpecifics has in achieving its goals; the timing for Auxilium to initiate next stage trials of CCH for frozen shoulder syndrome; and the timing for BioSpecifics' reporting top-line data from tis human and canine lipoma trials. In some cases, these statements can be identified by forward-looking words such as "b
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioSpecifics Technologies Corp. Reports Third Quarter 2013 Financial Results
2. BioSpecifics Technologies Corp. to Present at the Aegis Capital 2013 Healthcare Conference
3. BioSpecifics Technologies Corp. to Present at the Stifel Nicolaus 2013 Healthcare Conference
4. BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2013 Financial Results on Thursday, August 8, 2013
6. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
7. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
8. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
10. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
11. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  As the pharmaceutical industry works to ... Compliance professionals are placing a significant emphasis on ... today by LRN, the leader in Ethics & ... of respondents expressed that clarity on company values ... E&C training programs (57%), trumping understanding of the ...
(Date:3/5/2015)... 2015 Bayer HealthCare announced today that it ... Foundation of the American Society of Clinical Oncology (ASCO) ... platform designed to unlock vast quantities of information about ... "Bayer is proud to join ASCO and the ... Data to help people whose lives have been affected ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... 24, 2011 Genelux Corporation, a privately held, clinical ... cancer and inflammatory diseases, today announced the appointment of ... Board of Directors. Dr. Fenton,s appointment expands the Genelux ... someone who helped to build one of the world,s ...
... VIEW, Calif., Jan. 24, 2011 Based on its ... market, Frost & Sullivan recognizes BeClose with the 2010 ... of the Year for its innovative BeClose System and ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) While PERS have ...
Cached Medicine Technology:Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 3Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 4
(Date:3/5/2015)... (PRWEB) March 05, 2015 Central Nebraska ... their practice including the brand’s new logo and optimized ... showcase the practice’s modern approach to expert diagnostic imaging, ... mobile-optimized and be built to be a resource for ... community. With automated forms, communication and referral functionality, video ...
(Date:3/5/2015)... 05, 2015 On March 2, 2015, ... Labiaplasty on the Rise, Plastic Surgeons Say,” that comments ... Society for Aesthetic Plastic Surgery and the ... reported a year-over-year doubling of surgical butt augmentations performed ... in the article, this increase can be attributed to ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 Dr. ... Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... New York Metro area. Dr. Glashow has been selected ... authoritative guide to the top specialty care doctors in ... The prestigious Castle Connolly program, which carefully screens and ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... 2009, Octapharma AG realized a ... euro as of year-to-date June 2008, an increase of 27%. ... of sales increased proportionally more than the turnover, decreasing gross ... costs. , Due to increased efficacy in other areas, Octapharma ...
... patients , FRIDAY, Oct. 2 (HealthDay News) -- Treatment ... surgery in ulcerative colitis patients by almost half, a ... of the colon and often leads to surgical removal ... patients who received either an inactive placebo or infliximab ...
... not cell type, may lead to better treatments, researchers ... new way to classify stomach cancers could lead to ... with the disease, researchers say. , For a study ... the researchers analyzed 301 stomach tumors from people in ...
... , HOUSTON, Oct. 2 Cyberonics, Inc. (Nasdaq: ... of EEG-based seizure detection to build on its position ... On October 1, 2009, Cyberonics entered into a License ... a range of technology and patents in exchange for ...
... Ill Anterior cruciate ligament (ACL) injuries are one of ... thousands of patients undergo reconstructive surgery to repair these injuries. ... 2009 issue of The Journal of Bone and Joint ... is increasing substantially and women and younger patients are more ...
... ... the Ziostation® 3D advanced visualization software to the French market as an integrated product. ... Montreuil, France ... advanced visualization and analysis software for medical imaging and Global Imaging Online, French ...
Cached Medicine News:Health News:Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market 2Health News:New Classification Proposed for Stomach Cancers 2Health News:Cyberonics Announces Epilepsy Technology Collaborations 2Health News:Cyberonics Announces Epilepsy Technology Collaborations 3Health News:Cyberonics Announces Epilepsy Technology Collaborations 4Health News:Teenagers and ACL: Tears common and additional surgery likely 2Health News:Ziosoft and Global Imaging Online Announce Reseller Agreement for France and Maghreb Area 2
... assayed quality control material used for ... electrolyte, metabolite, and CO-Oximeter instrumentation. The ... it the ideal choice for Bayer ... in three (3) levels for monitoring ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is an assayed quality control material ... blood gas, electrolyte, metabolite, and CO-Oximeter ... control makes it the ideal choice ... is available in three (3) levels ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
Medicine Products: